Merck’s KEYTRUDA and Padcev show positive results in muscle-invasive bladder cancer
Merck (NYSE:MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy.



-640x358.jpg&w=3840&q=75)

-1-640x358.jpg&w=3840&q=75)




